Reporting requirements for marketing-authorisation holders
Submitted by Anonymous (not verified) on 6 October 2026 - 15:56
Reporting requirements for marketing-authorisation holders
Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 6 October 2026 - 15:50
Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 7, Status: Authorised
PRAC rules of procedure
Submitted by Anonymous (not verified) on 6 October 2026 - 15:46
PRAC rules of procedure
Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 6 October 2026 - 15:42
Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised
Concept paper on the guideline revision on good pharmacogenomic practice
Submitted by Anonymous (not verified) on 6 October 2026 - 15:40
Concept paper on the guideline revision on good pharmacogenomic practice
Agenda - Management Board meeting: 30 September 2026
Submitted by Anonymous (not verified) on 6 October 2026 - 15:15
Agenda - Management Board meeting: 30 September 2026
Management Board meeting: 30 September 2026, European Medicines Agency, Amsterdam, the Netherlands, 30 September 2026
Submitted by Anonymous (not verified) on 6 October 2026 - 15:15
Management Board meeting: 30 September 2026, European Medicines Agency, Amsterdam, the Netherlands, 30 September 2026
PSUSA/00001584/202602
Submitted by Anonymous (not verified) on 6 October 2026 - 15:04
PSUSA/00001584/202602
PSUSA/00001955/202602
Submitted by Anonymous (not verified) on 6 October 2026 - 15:00
PSUSA/00001955/202602
PSUSA/00001248/202602
Submitted by Anonymous (not verified) on 6 October 2026 - 14:56
PSUSA/00001248/202602